NXL
Nexalin Technology Inc.
NASDAQ: NXL · HEALTHCARE · MEDICAL DEVICES
$0.36
+2.42% today
Updated 2026-04-30
Market cap
$8.34M
P/E ratio
—
P/S ratio
27.63x
EPS (TTM)
$-0.50
Dividend yield
—
52W range
$0 – $2
Volume
0.6M
Nexalin Technology Inc. (NXL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $207383.00 | $242914.00 | $144065.00 | $1.32M | $110748.00 | $168721.00 | $301647.00 |
| Revenue growth (YoY) | — | +17.1% | -40.7% | +817.2% | -91.6% | +52.3% | +78.8% |
| Cost of revenue | $218210.00 | $29039.00 | $21442.00 | $363212.00 | $25688.00 | $36593.00 | $1.94M |
| Gross profit | $-10827.00 | $213875.00 | $122623.00 | $958145.00 | $85060.00 | $132128.00 | $-1.64M |
| Gross margin | -5.2% | 88.0% | 85.1% | 72.5% | 76.8% | 78.3% | -543.4% |
| R&D | — | — | $139000.00 | $511000.00 | $1.92M | $1.19M | $1.08M |
| SG&A | $78133.00 | $3.47M | $6.14M | $2.79M | $574598.00 | $966815.00 | $7.55M |
| Operating income | $-1.47M | $-3.26M | $-6.02M | $-1.83M | $-5.70M | $-7.75M | $-8.39M |
| Operating margin | -707.0% | -1341.4% | -4177.7% | -138.7% | -5143.5% | -4596.1% | -2781.7% |
| EBITDA | $-1.47M | $-3.32M | $-6.00M | $-1.83M | $-5.69M | $-7.74M | $-8.39M |
| EBITDA margin | -706.7% | -1368.5% | -4161.4% | -138.3% | -5139.6% | -4587.2% | -2781.7% |
| EBIT | $-1.47M | $-3.32M | $-6.00M | $-1.83M | $-5.70M | $-7.75M | $-8.41M |
| Interest expense | $80989.00 | $78681.00 | $82319.00 | $59382.00 | $38835.00 | $3193.00 | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-5.02M | $-3.40M | $-6.08M | $-1.70M | $-4.65M | $-7.61M | $-8.22M |
| Net income growth (YoY) | — | +32.2% | -78.6% | +72.1% | -173.8% | -63.6% | -8.1% |
| Profit margin | -2421.2% | -1401.1% | -4218.9% | -128.5% | -4197.6% | -4508.7% | -2725.8% |